Cerebrolysin vs Dihexa
Porcine brain-derived neuropeptide preparation containing bioactive peptide fragments of neurotrophic factors, used clinically in over 40 countries for stroke recovery, traumatic brain injury, and cognitive impairment
Angiotensin IV-derived oligopeptide that potentiates hepatocyte growth factor to drive synaptogenesis and cognitive enhancement with extraordinary potency
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Quick comparison
Dose range
Cerebrolysin
20–30 mL
Dihexa
8–20 mg
Frequency
Cerebrolysin
Once daily
Dihexa
Once daily
Administration
Cerebrolysin
Intravenous (IV) injection or infusion
Dihexa
Oral (capsule/tablet)
Cycle length
Cerebrolysin
8-12 weeks
Dihexa
4-6 weeks
Onset speed
Cerebrolysin
Moderate (1-2 weeks)
Dihexa
Moderate (1-2 weeks)
Evidence level
Cerebrolysin
Moderate human trials (Phase 1-2)
Dihexa
Preclinical only — animal and cell-culture studies; no human trials
Benefit ratings
Stroke Recovery
Alzheimer's Support
Brain Injury Healing
Cognitive
Healing & Recovery
Anti-Aging
Compound specifications
Cerebrolysin
Molecular formula
Complex mixture — no single molecular formula (contains multiple peptide fragments and free amino acids derived from porcine brain proteins)
Molecular weight
Bioactive peptide components are all below 10 kDa (10,000 Da); the preparation contains a spectrum of peptide sizes
Half-life
Approximately 15-30 minutes (IV administration)
Bioavailability
~85-100% (intramuscular injection)
CAS number
Not assigned (biological mixture)
Dihexa
Molecular formula
C27H44N4O5
Molecular weight
504.7 g/mol
Half-life
~12 days (following IV administration in rats)
Bioavailability
Orally active and blood-brain barrier permeable — specific oral bioavailability percentage not published
CAS number
1401708-83-5
Dosing compared
Cerebrolysin
Intravenous
10 mL
Once daily · 10-20 day course, repeated every 3-6 months
A gentle starting dose given as a slow IV infusion (often diluted in saline). Used in dementia and recovery programs. [6][7]
20-30 mL
Once daily · 10-21 day course, repeated in cycles
The common clinical dose. Trials in vascular dementia used 20 mL daily, and stroke trials used 30 mL daily (diluted to about 100 mL saline) infused over ~30 minutes. [6][7]
30-50 mL
Once daily · 10-21 days for stroke or severe brain injury
The higher end used for acute stroke and severe traumatic brain injury, given as a diluted IV infusion under medical supervision. [7]
Intramuscular
5-10 mL
Once daily · Up to 10-20 days per course
For smaller doses, Cerebrolysin can be given as an intramuscular injection (no more than ~5 mL per injection site). Often used for milder cases or maintenance between IV cycles. [7]
Dihexa
Oral
5–8 mg
Once daily · 2–4 weeks
Lower starting amount reported in practice. Dihexa has no human clinical trials, so all amounts come from animal research and community use [2][4].
8–20 mg
Once daily · 4–6 weeks
Commonly reported daily range in practice for cognitive support [2][4].
20–45 mg
Once daily · 4–6 weeks, then reassess
Upper end of amounts reported in practice. No long-term human safety data exists, so this should be approached with caution [2][4].
Sublingual
5–15 mg
Once daily · 4–6 weeks
Held under the tongue as an alternative to swallowing; amounts reported in practice are similar to oral use [4].
Topical
5–15 mg in DMSO carrier
Once daily · 4–6 weeks
Applied to the skin in a DMSO solution to help absorption; used in practice as a non-oral option [4].
Best suited for
Cerebrolysin
Post-stroke neurorecovery and rehabilitation support
Cerebrolysin is particularly well-suited for individuals focused on post-stroke neurorecovery and rehabilitation support. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [2][13].
Cognitive support in Alzheimer's disease and vascular dementia
Cerebrolysin is particularly well-suited for individuals focused on cognitive support in alzheimer's disease and vascular dementia. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [1][6].
Traumatic brain injury recovery and neuroprotection
Cerebrolysin is particularly well-suited for individuals focused on traumatic brain injury recovery and neuroprotection. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [14].
Age-related cognitive decline and mild cognitive impairment
Cerebrolysin is particularly well-suited for individuals focused on age-related cognitive decline and mild cognitive impairment. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [1].
Dihexa
Age-Related Cognitive Decline
Dihexa directly addresses the synaptic loss that underlies age-related cognitive decline by building new functional synaptic connections in the hippocampus. Animal studies demonstrate restored spatial learning in aged rats, [6] making it a compelling candidate for combating memory loss associated with aging.
Neuroplasticity Enhancement
Unlike nootropics that work through neurotransmitter modulation, dihexa drives physical neuroplasticity — the formation of new dendritic spines and synapses. [6] This makes it ideal for individuals looking to enhance their brain's capacity for learning and adaptation at a structural level.
Neurodegenerative Disease Research
Preclinical evidence in APP/PS1 Alzheimer's mice and scopolamine-induced amnesia models [4][6] positions dihexa as a leading research compound for neurodegenerative disease. It is patented for potential use in Alzheimer's and Parkinson's diseases, with ongoing interest from the research community.
Advanced Nootropic Stacking
Dihexa's unique mechanism (HGF/c-Met potentiation) is complementary to most other nootropic mechanisms, making it an excellent addition to advanced cognitive enhancement protocols when combined with choline donors, racetams, or adaptogens.
Side effects
Cerebrolysin
Common
- Injection site reactions
- Headache
- Dizziness and vertigo
- Nausea and gastrointestinal discomfort
- Agitation or restlessness
- Fever
Uncommon
- Allergic reaction
Serious
- Severe hypersensitivity reaction
Dihexa
Common
- Headache
- Vivid dreams or altered sleep patterns
- Emotional sensitivity
- Mild fatigue during adjustment
Uncommon
- Gastrointestinal discomfort
Serious
- Theoretical oncogenic risk from c-Met activation
Safety & evidence
Cerebrolysin
Evidence level
Moderate human trials (Phase 1-2)
FDA status
Research compound
Safety overview
Cerebrolysin is an FDA-unregulated neuroprotective agent consisting of porcine brain-derived peptides and amino acids that has been used primarily in Eastern Europe and Asia. [8][12] Safety data is limited to observational clinical use and small open-label trials rather than rigorous randomized controlled trials with formal safety monitoring. As a complex mixture of undefined peptide fragments from animal sources, batch consistency and sterility cannot be guaranteed without pharmaceutical manufacturing standards. Potential allergic reactions to porcine proteins and transmissible spongiform encephalopathy (TSE) risks from animal-derived components have not been adequately ruled out.
Contraindications
- Known hypersensitivity to Cerebrolysin or porcine-derived products
- Severe renal impairment or renal failure
- Status epilepticus or uncontrolled epilepsy
- Pregnancy and breastfeeding — insufficient safety data
Dihexa
Evidence level
Preclinical only — animal and cell-culture studies; no human trials
FDA status
Research compound
Safety overview
Dihexa has demonstrated a favorable safety profile in published animal studies, with no reported tumorigenic effects or organ toxicity at cognitive-enhancing doses. However, the compound has not undergone formal human clinical trials, and long-term safety data does not exist. [7] The primary theoretical safety concern is sustained activation of the HGF/c-Met proto-oncogenic pathway, which could theoretically promote tumor initiation or growth. [7] The extremely long half-life (~12 days) [6][7] raises additional concerns about compound accumulation with chronic daily dosing. Anecdotal reports from the nootropics community generally describe good tolerability at doses of 5-20 mg daily, with headaches and vivid dreams as the most commonly reported effects.
Contraindications
- Known or suspected malignancy — c-Met/HGF pathway activation may promote tumor growth
- Pregnancy and breastfeeding — no safety data available
- History of cancer, particularly HGF/c-Met-driven tumors (hepatocellular, gastric, lung)
- Severe hepatic impairment
Which is right for you?
Choose Cerebrolysin if...
- Post-stroke neurorecovery and rehabilitation support
- Cognitive support in Alzheimer's disease and vascular dementia
- Traumatic brain injury recovery and neuroprotection
- Age-related cognitive decline and mild cognitive impairment
Choose Dihexa if...
- Cognitive enhancement and memory consolidation in age-related decline
- Supporting neuroplasticity and new synaptic connection formation
- Research into neurodegenerative disease therapeutics (Alzheimer's, Parkinson's)
- Nootropic stacking for individuals seeking enhanced learning capacity